Singh Pawan K, Pan Edward
University of California, Irvine, USA.
University of Texas Southwestern Medical Center, USA.
J Neurol Sci. 2020 Mar 15;410:116649. doi: 10.1016/j.jns.2019.116649. Epub 2019 Dec 25.
Primary CNS lymphoma (PCNSL) is a rare intracranial tumor. Several treatment regimens exist, but there is no one established standard of care regimen. This article reviews the effects of the addition of rituximab to induction chemotherapy for PCNSL patients. The addition of rituximab in phase II trials seems to increase the overall response rates (ORR) of PCNSL patients, especially when they receive consolidation therapy after rituximab-based induction chemotherapy regimens. Upfront rituximab added to MBVP chemotherapy did not improve overall survival in PCNSL patients, but it may benefit specific subpopulations of PCNSL patients. This review highlights the potential benefit of rituximab as part of induction chemotherapy with consolidation treatment.
原发性中枢神经系统淋巴瘤（PCNSL）是一种罕见的颅内肿瘤。现有多种治疗方案，但尚无一种既定的标准治疗方案。本文综述了利妥昔单抗添加至PCNSL患者诱导化疗中的效果。在II期试验中添加利妥昔单抗似乎可提高PCNSL患者的总缓解率（ORR），尤其是当他们在基于利妥昔单抗的诱导化疗方案后接受巩固治疗时。在MBVP化疗中预先添加利妥昔单抗并未改善PCNSL患者的总生存期，但可能使PCNSL患者的特定亚群受益。本综述强调了利妥昔单抗作为诱导化疗联合巩固治疗一部分的潜在益处。
